About Venatorx Pharmaceuticals
Venatorx Pharmaceuticals is a private pharmaceutical company focused on antibiotics and antivirals.
57 articles about Venatorx Pharmaceuticals
Venatorx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI), including Pyelonephritis, in Adults
Venatorx Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic for the potential treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis.
Venatorx Pharmaceuticals Highlights Two Recent Publications Indicating Rising Metallo-Beta-Lactamases for Carbapenem-Resistant Enterobacterales in US
Venatorx Pharmaceuticals today highlights two recent publications that provide important updates on the changing epidemiology of carbapenem-resistant Enterobacterales (CRE) globally and in the United States (US).
Venatorx Pharmaceuticals today announced changes to its Board of Directors.
Venatorx Pharmaceuticals today announced two organizational changes: the retirement of its Chief Medical Officer, Timothy Henkel, M.D., Ph.D., and the step-down of Vincent Milano from the Board of Directors.
Venatorx Pharmaceuticals today will present new data during IDWeek 2022 for its novel investigational antibiotic cefepime-taniborbactam.
Venatorx Pharmaceuticals today announced six presentations during IDWeek 2022, October 19-23, 2022, in Washington, DC.
Venatorx Pharmaceuticals today announced the Biomedical Advanced Research and Development Authority has awarded the company a contract to support the development of cefepime-taniborbactam for the treatment of melioidosis.
4/6/2022The AMR Action Fund financed two of this week’s money moves. Other moves ranged from medical devices to wearable sensor data companies. For that and more, continue reading.
Venatorx Pharmaceuticals, Inc. announced that it sold shares of its Series C Preferred Stock in a financing led by the AMR Action Fund with participation from existing investors including Abingworth.
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI
Venatorx Pharmaceuticals announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections, including acute pyelonephritis.
Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial
Everest Medicines announced that its licensing partner, Venatorx Pharmaceuticals, reported positive results from its pivotal Phase 3 study, CERTAIN-1, evaluating cefepime-taniborbactam, an investigational new drug, versus meropenem as a potential treatment for hospitalized adult patients with complicated urinary tract infections, including acute pyelonephritis.
Venatorx Pharmaceuticals shared that its Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.
Venatorx Pharmaceuticals today announced that Scott McConnell, Pharm.D. has joined the Company as Vice President, Medical Affairs.
Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen
Venatorx Pharmaceuticals announced today that it has entered into a Research Collaboration and License Agreement with Roche to discover, characterize and develop new small molecule inhibitors of the Penicillin Binding Proteins (“PBPs”)
Less private investment and innovation in the development of new antibiotics are impeding efforts to combat drug-resistant infections.
Venatorx Pharmaceuticals today announced that the Company, along with its collaborators, will present seven posters and two oral abstracts at IDWeek 2021, which is taking place virtually September 29 – October 3, 2021.
Venatorx Pharmaceuticals today announced a comprehensive update about cefepime-taniborbactam, the Company’s intravenous beta-lactam / beta-lactamase inhibitor (BL/BLI)
Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial (ClinicalTrials.gov – NCT04243863) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.
Venatorx Pharmaceuticals today announced that Mary Beth Dorr, Ph.D. has joined the Company as Vice President, Clinical Science.